natgillin/translations-raw huggingface dataset:
Triglycerides, HDL cholesterol and albumin did not change. 
Trigliceridi, HDL holesterol in albumin se niso spremenili.
Your doctor will check for interactions between Tasermity and other medicines on a regular basis. 
Vaš zdravnik bo redno preverjal medsebojno delovanje zdravila Tasermity in ostalih zdravil.
ATC code: V03AE02. 
Oznaka ATC: V03AE02.
The recommended starting dose of Tasermity for adults and the elderly (> 65 years) is one or two tablets with each meal 3 times a day. 
Priporočljiv začetni odmerek zdravila Tasermity za odrasle in starejše (> 65 let) je ena ali dve tableti pri vsakem glavnem obroku 3 krat dnevno.
The marketing authorisation holder shall submit the first periodic safety update report for this product with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines webportal. 
Imetnik dovoljenja za promet z zdravilom mora prvo redno posodobljeno poročilo o varnosti zdravila za to zdravilo predložiti v skladu z zahtevami, določenimi v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in objavljenem na evropskem spletnem portalu o zdravilih.
Do not use this medicine after the expiry date stated on the bottle after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki poleg oznake: “EXP”.
37 Hollands Road Haverhill, Suffolk CB9 8PU United Kingdom 
37 Hollands Road Haverhill, Suffolk CB9 8PU Velika Britanija
The amount of phosphate then rises (your doctor will call this hyperphosphataemia). 
Zato količina fosfatov narašča (vaš zdravnik temu pravi hiperfosfatemija).
As data on the chronic use of sevelamer hydrochloride for over one year are not yet available, potential absorption and accumulation of sevelamer during long-term chronic treatment cannot be totally excluded (see section 5.2). 
Ker podatki o kronični uporabi sevelamera več kot eno leto še niso na voljo, možne absorpcije in kopičenja sevelamerijevega klorida v dolgotrajnem kroničnem zdravljenju ni možno povsem izključiti (glejte poglavje 5.2).
This risk can be reduced by careful adherence to sterile techniques during bag changes. 
To tveganje se lahko zmanjša s strogim upoštevanjem sterilnih tehnik med zamenjavo vrečk.
Bioavailability 
Biorazpoložljivost
• if you are allergic to sevelamer or to any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na sevelamer ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Since Tasermity does not contain calcium your doctor might prescribe additional calcium tablets. 
Ker zdravilo Tasermity ne vsebuje kalcija, vam utegne zdravnik predpisati dodatne kalcijeve tablete.
Sevelamer hydrochloride must be taken three times per day with meals. 
Sevelamerijev klorid je treba jemati trikrat na dan z obroki.
• if you have low levels of phosphate in your blood (your doctor will check this for you). 
• če imate nizko koncentracijo fosfatov v krvi (vaš zdravnik bo opravil pregled),
1 tablet, 3 times per day 2 tablets, 3 times per day 
3-krat na dan po 2 tableti
Therefore, patients on PD should be closely monitored to ensure the reliable use of appropriate aseptic technique with the prompt recognition and management of any signs and symptoms associated with peritonitis. 
Zato je treba bolnike na peritonealni dializi skrbno nadzirati, da se zagotovi zanesljiva uporaba ustreznih aseptičnih tehnik in hitro prepoznavanje in obravnavanje vseh znakov in simptomov, povezanih s peritonitisom.
Do not chew. 
Ne žvečite jih.
Pharmacokinetic studies have not been carried out in renal failure patients (see section 4.4). 
Farmakokinetične raziskave niso bile izpeljane pri bolnikih z ledvično odpovedjo (glejte poglavje 4.4).
Elemental calcium should be given as a supplement in case of hypocalcaemia. 
Elementarni kalcij se daje kot dodatek v primeru hipokalciemije.
Serum phosphate should be tested every two to three weeks until a stable serum phosphate level is reached and on a regular basis thereafter. 
Fosfat v serumu je treba preverjati vsake dva do tri tedne, dokler ni dosežena stabilna koncentracija fosfata v serumu, in potem redno.
uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
Neželeni učinki se po poročani pogostosti ocenjujejo kot zelo pogosti (1/10), pogosti (1/100 do <1/10), občasni (1/1.000 do <1/100), redki (1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The recommended starting dose of sevelamer hydrochloride is 2.4 g or 4.8 g per day based on clinical needs and serum phosphorus level. 
Priporočen začetni odmerek sevelamerijevega klorida je 2,4 g ali 4,8 g na dan glede na klinične potrebe in ravni serumskega fosforja.
In reproduction studies there was no evidence that sevelamer induced embryolethality, foetotoxicity or teratogenicity at the doses tested (up to 1 g/kg/day in rabbits and up to 4.5 g/kg/day in rats). 
Pri raziskavah reprodukcije ni bilo dokazov, da bi sevelamer povzročil smrtnost zarodka, fetotoksičnost ali teratogenost pri preizkusnih odmerkih (do 1 g/kg/dan pri zajcih in do 4,5 g/kg/dan pri podganah).
What you need to know before you take Tasermity 3. 
Kaj morate vedeti, preden boste vzeli zdravilo Tasermity 3.
Initially your doctor will check the levels of phosphate in your blood every 2-3 weeks and may adjust the dose of Tasermity when necessary (between 1 and 5 tablets of 800 mg per meal) to reach an adequate phosphate level. 
Vaš zdravnik bo na začetku zdravljenja na vsake 2-3 tedne preveril raven fosfatov v vaši krvi in bo morda odmerek zdravila Tasermity spremenil, če bo potrebno (med 1 in 5 tabletami po 800 mg na obrok), da bi na ta način dosegel ustrezno raven fosfatov.
Additional treatments: Due to either your kidney condition or your dialysis treatment you may: 
Dodatna zdravljenja: Zaradi ledvičnih težav ali zdravljenja z dializo vam lahko:
• Hypersensitivity to sevelamer or to any of the excipients listed in section 6.1. 
• preobčutljivost na sevelamer ali katero koli pomožno snov, navedeno v poglavju 6.1
Pharmacotherapeutic group: Treatment of hyperphosphatemia. 
Farmakoterapevtska skupina: Zdravljenje hiperfosfatemije.
What Tasermity is and what it is used for 2. 
Kaj je zdravilo Tasermity in za kaj ga uporabljamo 2.
Since constipation may be a preceding symptom in very rare cases of blockages in your intestine, it is important to inform your doctor or pharmacist of this symptom before or during the use of Tasermity. 
Ker je lahko zaprtost v zelo redkih primerih zgodnji simptom blokade v črevesju, je pomembno, da pred ali med uporabo zdravila Tasermity o tem obvestite svojega zdravnika ali farmacevta.
Genzyme Europe B.V., Gooimeer 10, 1411 DD Naarden, the Netherlands 
IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM Genzyme Europe B.V., Gooimeer 10, 1411 DD Naarden, Nizozemska.
Also the medicinal product is not absorbed in the gastrointestinal tract. 
Zdravilo se ne absorbira v gastrointestinalni trakt.
There is at present insufficient data to exclude the possibility of folate deficiency during long term sevelamer hydrochloride treatment. 
Trenutno ni dovolj podatkov, da bi izključili možnost pomanjkanja folatov med dolgotrajnim zdravljenjem s sevelamerijevim kloridom.
• Tasermity should not be taken at the same time as ciprofloxacin (an antibiotic). 
• Zdravila Tasermity ne smete jemati sočasno s ciprofloksacinom (antibiotik).
These amines become partially protonated in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. 
Ti amini postanejo delno protonirani v črevesju in medsebojno delujejo s fosfatnimi molekulami prek ionske in vodikove vezi.
Sevelamer hydrochloride is not absorbed and may affect the bioavailability of other medicinal products. 
Sevelamerijev klorid se ne absorbira in lahko vpliva na biološko uporabnost drugih zdravil.
However, the causality of the sevelamer crystals in initiating such disorders has not been demonstrated. 
Vendar vzročna povezanost prisotnosti kristalov sevelamerja pri nastanku takšnih bolezni ni bila dokazana.
Patients with chronic renal failure are predisposed to developing metabolic acidosis. 
Bolniki s kronično ledvično odpovedjo so nagnjeni k razvoju metabolične acidoze.
When administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer hydrochloride, or the physician should consider monitoring blood levels. 
Pri dajanju katerih koli zdravil, pri katerih ima lahko zmanjšanja biološka uporabnost klinično značilen vpliv na varnost ali učinkovitost, je treba zdravilo dati vsaj eno uro pred ali tri ure po uporabi sevelamerijevega klorida, ali pa mora zdravnik razmisliti o nadzoru ravni v krvi.
Do not crush, chew or break into pieces prior to administration. 
Ne sme se jih zdrobiti, žvečiti ali zlomiti na koščke pred uporabo.
You should tell your doctor immediately if you experience any new signs or symptoms of abdominal distress, abdominal swelling, abdominal pain, abdominal tenderness, or abdominal rigidity, constipation, fever, chills, nausea or vomiting. 
Takoj morate sporočiti svojemu zdravniku, če zasledite kakršne koli nove znake ali simptome neugodja, napihnjenosti, bolečine, napetosti ali togosti v trebuhu, zaprtost, zvišano telesno temperaturo, mrzlico, slabost ali bruhanje.
• patients with a history of major gastrointestinal surgery 
• pri bolnikih, ki so imeli v preteklosti obsežno gastrointestinalno operacijo
Abdominal pain, intestinal obstruction, ileus/subileus, diverticulitis, intestinal perforation 
bolečina v trebuhu, obstrukcija črevesja, ileus/subileus, divertikulitis, perforacija črevesja
The following side effects have been reported in patients taking Tasermity: Very common (may affect more than 1 in 10 people): nausea, vomiting 
Naslednji neželeni učinki se običajno pojavijo pri bolnikih, ki jemljejo zdravilo Tasermity: Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov): siljenje na bruhanje, bruhanje
Serum chloride 
Klorid v serumu
Your doctor will advise you if you are taking these medicines. 
Vaš zdravnik vam bo svetoval,
One gram of sevelamer hydrochloride contains approximately 180 mg (5.1 mEq) chloride. 
En gram sevelamerijevega klorida vsebuje približno 180 mg (5,1 mEq) klorida.
Sevelamer decreases the incidence of hypercalcaemic episodes as compared to patients using calcium based phosphate binders alone, probably because the product itself does not contain calcium. 
Sevelamer zmanjša število pojavov hiperkalcemije v primerjavi z bolniki, ki uživajo le fosfatne vezalce na osnovi kalcija, verjetno zaradi tega, ker zdravilo samo ne vsebuje kalcija.
Deficits in skeletal ossification were observed in several locations in fetuses of female rats dosed with sevelamer at 8-20 times the maximum human dose of 200 mg/kg. 
Pomanjkanje okostenelosti skeleta je bilo opaziti pri več zarodkih podganjih samic, ki so dobivale odmerek sevelamera, ki je bil 8 do 20-krat večji od najvišjega odmerka za ljudi, ki znaša 200 mg/kg.
Serum phosphate levels should be closely monitored and the dose of sevelamer hydrochloride titrated by 0.8 g three times per day (2.4 g/day) increments with the goal of lowering serum phosphate to 1.76 mmol/L (5.5 mg/dl) or less. 
Koncentracijo fosfata v serumu je treba skrbno spremljati in odmerek sevelamerijevega klorida titrirati z 0,8 g odmerkom trikrat na dan (2,4 g/dan) glede na cilj znižanja fosfata v serumu na 1,76 mmol/l (5,5 mg/dl) ali manj.
It contains multiple amines separated by one carbon from the polymer backbone. 
Vsebuje več aminov, ki jih loči ogljik iz polimerne verige.
Patients receiving dialysis are subject to certain risks for infection specific to the dialysis modality. 
Bolniki na dializi so izpostavljeni nekaterim tveganjem za okužbe, ki so odvisne od načina dialize, ki jo prejemajo.
In some cases where Tasermity should be taken at the same time as another medicine, your doctor may advise you to take this medicine 1 hour before or 3 hours after Tasermity intake, or he/she may consider monitoring the blood levels of that medicine. 
V nekaterih primerih, ko je treba zdravilo Tasermity vzeti sočasno z drugim zdravilom, vam bo zdravnik morda svetoval, da vzamete drugo zdravilo 1 uro pred ali 3 ure po vnosu zdravila Tasermity ali pa se bo odločil za nadziranje ravni tega zdravila v krvi.
The effects may be secondary to vitamin D and/or vitamin K depletion at these high doses. 
Ti učinki so lahko posledica pomanjkanja vitamina D in/ali vitamina K pri tako visokih odmerkih.
You should expect to be monitored more carefully for problems with low levels of vitamins A, D, E, K and folic acid. 
Poleg tega pričakujte, da vas bodo skrbno spremljali glede težav zaradi nizkih ravni vitaminov A, D, E, K in folne kisline.
• In certain people taking levothyroxine (a thyroid hormone) and Tasermity, increased levels of thyroid stimulating hormone (TSH, a substance in your blood which helps control your body's chemical functions) may very rarely be observed. 
• Pri nekaterih ljudeh, ki jemljejo levotiroksin (tiroidni hormon) in zdravilo Tasermity, so zelo redko opazili zvišane ravni tiroideo stimulirajočega hormona (TSH, snov v krvi, ki pomaga nadzirati kemijske funkcije telesa).
Not known (frequency cannot be estimated from the available data): cases of itching, rash, abdominal pain, slow intestine motility (movement), blockages in the intestine, inflammation of abnormal small pouches (called diverticula) in the large intestine and perforation in the intestine wall have been reported. 
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti): Poročali so o primerih srbečice, izpuščaja, bolečin v trebuhu, počasne gibljivosti (premikanja) črevesja, blokad v črevesju, vnetja nenormalnih majhnih žepkov (imenovanih divertikli) v debelem črevesu in perforacije stene črevesja.
In animal studies there was no evidence that sevelamer induced embryo-foetal toxicity. 
Študije na živalih niso pokazale embriofetalne toksičnosti, povzročene s sevelamerom.
• if you have prolonged diarrhoea or pain in the abdomen (symptoms of active inflammatory bowel disease) 
• imate podaljšano trajanje driske ali bolečine v trebuhu (simptomi vnetne črevesne bolezni)
• If you are taking medicine such as omeprazole, pantoprazole, or lansoprazole to treat heartburn, gastroesophageal reflux disease (GERD), or gastric ulcers, you should consult your doctor when taking Tasermity. 
• Če jemljete zdravila kot so omeprazol, pantoprazol ali lansoprazol za zdravljenje zgage, gastroezofagealne refluksne bolezni (GERB) ali želodčnih razjed, se o jemanju zdravila Tasermity posvetujte s svojim zdravnikom.
Therefore, in patients not taking these vitamins, monitoring vitamin A, D and E levels and assessing vitamin K status through the measurement of thromboplastin time should be considered and the vitamins should be supplemented if necessary. 
Zato je treba pri bolnikih, ki teh vitaminov ne jemljejo, razmisliti o nadzoru ravni vitaminov A, D in E ter ocenjevanje stanja vitamina K z merjenjem tromboplastinskega časa in po potrebi dodajati vitamine.
Special note for patients on peritoneal dialysis: 
Posebno opozorilo bolnikom, ki prejemajo peritonealno dializo:
If you forget to take Tasermity 
Če ste pozabili vzeti zdravilo Tasermity
Other medicines and Tasermity 
Druga zdravila in zdravilo Tasermity
The dose range may vary between 1 and 5 tablets of 800 mg per meal. 
Odmerek je lahko od 1 do 5 tablet po 800 mg pri enem obroku.
Cases of serious inflammatory disorders of different parts of the gastrointestinal tract (including serious complications such as bleeding, perforation, ulceration, necrosis, colitis, …) associated with the presence of sevelamer crystals have been reported in literature. 
V literaturi so bili opisani primeri resnih vnetnih bolezni različnih delov prebavil (vključno z resnimi zapleti, kot so npr. krvavitev, perforacija, ulceracija, nekroza, kolitis, ...), povezanih s prisotnostjo kristalov sevelamerja.
Very rare (may affect up to 1 in 10000 people): hypersensitivity. 
Zelo redki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): preobčutljivost
Anti-arrhythmics and anti-seizure medicinal products Patients taking anti-arrhythmic medicinal products for the control of arrhythmias and anti-seizure medicinal products for the control of seizure disorders were excluded from clinical trials. 
Antiaritmiki in antiepileptična zdravila za nadzor epileptičnih napadov Bolniki, ki jemljejo antiaritmična zdravila za nadzor aritmij in antiepileptična zdravila za nadzor epileptičnih napadov, so bili izključeni iz kliničnih preskušanj.
Closer monitoring of serum bicarbonate levels is therefore recommended. 
Zato se priporoča skrbno nadziranje ravni hidrogenkarbonata v serumu.
In clinical trials mean total and LDL cholesterol declined by 15-31%. 
Pri kliničnih preskušanjih je povprečna vrednost skupnega holesterola in holesterola LDL upadla za 1531 %.
Tasermity should only be given to pregnant or breast-feeding women if clearly needed. 
Zdravilo Tasermity se sme dajati nosečnicam ali doječim ženskam le, kadar je nujno potrebno.
Sevelamer hydrochloride has been given to normal healthy volunteers in doses up to 14 grams, the equivalent of seventeen 800 mg tablets, per day for eight days with no undesirable effects. 
Sevelamerijev klorid so dajali zdravim prostovoljcem v odmerkih do 14 gramov na dan, kar je enakovredno petintridesetim tabletam po 800 mg, osem dni zaporedoma brez neželenih učinkov.
Consequently, sevelamer hydrochloride should not be taken simultaneously with ciprofloxacin. 
Zato se sevelamerijev klorid ne sme jemati istočasno s ciprofloksacinom.
Each bottle contains 180 film-coated tablets. 
Ena plastenka vsebuje 180 filmsko obloženih tablet.
Peritonitis is a known complication in patients receiving peritoneal dialysis (PD) and in a clinical study with sevelamer hydrochloride, a number of peritonitis cases were reported. 
Peritonitis je znan zaplet pri bolnikih, ki prejemajo peritonealno dializo (PD), in v kliničnih študijah s sevelamerijevim kloridom so poročali o številnih primerih peritonitisa.
The average actual daily dose used in the chronic phase of a one year clinical study was 7 grams of sevelamer hydrochloride. 
Povprečni dnevni odmerek sevelamerijevega klorida, ki so ga v enoletni klinični študiji dajali bolnikom v kronični fazi, je bil 7 gramov.
In interaction studies in healthy volunteers, sevelamer hydrochloride had no effect on the bioavailability of digoxin, warfarin, enalapril or metoprolol. 
Ko so preučevali medsebojno delovanje pri zdravih prostovoljcih, sevelamerijev klorid ni imel učinka na biološko uporabnost digoksina, varfarina, enalaprila ali metoprolola.
In interaction studies in healthy volunteers, sevelamer hydrochloride decreased the bioavailability of ciprofloxacin by approximately 50% when co-administered with sevelamer hydrochloride in a single dose study. 
V študijah medsebojnega delovanja pri zdravih prostovoljcih je sevelamerijev klorid zmanjšal biološko uporabnost ciprofloksacina za približno 50 % pri sočasni uporabi z zdravilom Tasermity v študiji z enim odmerkom.
The safety and efficacy in children (below the age of 18 years) have not been studied. 
Varnosti in učinkovitosti zdravila Tasermity pri otrocih (starih do 18 let) niso preučevali.
- The other ingredients are silica colloidal anhydrous and stearic acid, hypromellose (E464), diacetylated monoglycerides, iron oxide black (E172) and propylene glycol. 
- Pomožne snovi so brezvodni koloidni silicijev dioksid in stearinska kislina, hipromeloza (E464), diacetilirani monogliceridi, črni železov oksid (E172) in propilenglikol.
Serum calcium levels should be monitored as is done in normal follow-up of a dialysis patient. 
Nadzirati je treba ravni kalcija v serumu kot pri običajnem spremljanju bolnikov na dializi.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING LABEL with Blue Box - 1 BOTTLE OF 180 TABLETS 800 mg WITHOUT OUTER CARTON 
NALEPKA s tako imenovanim modrim okencem - 1 PLASTENKA S 180 TABLETAMI PO 800 mg BREZ ZUNANJE OVOJNINE
Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
When you switch from another phosphate binder to Tasermity, your doctor might consider monitoring the levels of bicarbonate in your blood more closely because Tasermity may decrease the levels of bicarbonate. 
Pri prehodu z drugega fosfatnega vezalca na zdravilo Tasermity je priporočljivo, da vaš zdravnik pazljiveje spremlja ravni hidrogenkarbonata v krvi, ker zdravilo Tasermity te ravni lahko zniža.
Additional monitoring of vitamins and folic acid is recommended in patients receiving peritoneal dialysis, since in the clinical study, vitamin A, D, E and K levels were not measured in these patients. 
Pri bolnikih na peritonealni dializi se priporoča dodatno nadziranje vitaminov in folne kisline, saj v klinični študiji ravni vitaminov A, D, E in K pri teh bolnikih niso merili.
However, in vitro and in vivo studies have indicated that sevelamer does not have genotoxic potential. 
Vendar pa so in vitro in in vivo raziskave pokazale, da sevelamer ni genotoksičen.
The possibility of an interaction cannot be excluded and a close monitoring of blood concentrations of mycophenolate mofetil, ciclosporin and tacrolimus should be considered during the use of combination and after its withdrawal. 
Možnost medsebojnega delovanja torej ni izključena, zato skrbno spremljajte koncentracije mikofenolat mofetila, ciklosporina in takrolimusa v krvi med uporabo te kombinacije in po njeni ukinitvi, če je potrebno.
What Tasermity looks like and contents of the pack 
Izgled zdravila Tasermity in vsebina pakiranja
If you have missed one dose, this dose should be omitted and the next dose should be taken at the usual time with a meal. 
Če pozabite vzeti odmerek, ga izpustite in naslednji odmerek vzemite kot običajno.
What Tasermity is and what it is used for 
Kaj je zdravilo Tasermity in za kaj ga uporabljamo
In preclinical studies in rats and dogs, sevelamer at a dose of 10 times the maximum human doses reduced absorption of fat soluble vitamins D, E and K, and folic acid. 
V predkliničnih raziskavah na podganah in psih je sevelamer v odmerku, ki je desetkrat večji od najvišjih odmerkov za ljudi, zmanjševal absorpcijo v maščobi topnih vitaminov D, E in K ter folne fisline.
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE 
IZDELOVALCI, ODGOVORNI ZA SPROŠČANJE SERIJ POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z
In the clinical studies in haemodialysis patients, sevelamer hydrochloride alone did not have a consistent and clinically significant effect on serum intact parathyroid hormone (iPTH). 
Med kliničnimi študijami pri bolnikih, ki se zdravijo s hemodializo, sam sevelamerijev klorid ni imel trajnega in klinično pomembnega učinka na intaktni paratiroidni hormon (iPTH).
• if you have swallowing problems 
• imate težave s požiranjem
Pack size: 1 bottle of 180 tablets 
Velikosti pakiranj so: 1 plastenka s 180 tabletami
Sevelamer hydrochloride should only be given to breast-feeding women if clearly needed and after a careful risk/benefit analysis has been conducted for both the mother and the infant (see section 5.3). 
Sevelamerijev klorid naj doječe ženske jemljejo le, če ga nujno potrebujejo in po skrbni analizi tveganja/koristi za mater in dojenčka (glejte poglavje 5.3).
For patients previously on phosphate binders, Sevelamer hydrochloride should be given on a gram for gram basis with monitoring of serum phosphorus levels to ensure optimal daily doses. 
Bolnikom, ki so prej jemali vezalce fosfata, je treba sevelamerijev klorid dajati na osnovi gram po gram ter pri tem nadzirati ravni fosforja v serumu, da se zagotovijo optimalni dnevni odmerki.